Previous 10 | Next 10 |
2023-09-19 07:23:07 ET More on Cytosorbents Seeking Alpha’s Quant Rating on Cytosorbents Historical earnings data for Cytosorbents Financial information for Cytosorbents Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call F...
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the wo...
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, highlights the growing moment...
2023-09-01 16:51:59 ET More on Cytosorbents CytoSorbents guides Q4 revenue above estimates CytoSorbents says Canada cleared pivotal study for anti-bleeding technology Cytosorbents draws $5M debt financing; extends loan agreement AMD, JD and BILI are among pre...
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that Alexander D...
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the wor...
CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial PR Newswire Readout of topline results expected before year-end on FDA Breakthrough Device, DrugSorb-ATR. Sets stage for potential regulatory submission to FDA and Health Canada as the first reversal agent f...
2023-08-01 21:25:04 ET Cytosorbents Corporation. (CTSO) Q2 2023 Earnings Conference Call August 01, 2023, 04:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Of...
2023-08-01 16:33:06 ET Cytosorbents press release ( NASDAQ: CTSO ): Q2 GAAP EPS of -$0.14 in-line. Revenue of $9.4M (+10.6% Y/Y) misses by $0.8M . Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points to 74% ...
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points to 74% PRINCETON, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corpo...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...